Keyword: Regeneron Pharmaceuticals
Kodiak Sciences has filed to raise up to $100 million in its IPO to support the development of its anti-VEGF drug for eye diseases.
The committee made the call after assessing the risk-benefit profile of the osteoarthritis regimens based on data generated to date.
If the pair finds potential treatments in the discovery deal, they will ink a new collaboration to advance them.
Aya Jakobovits is retaining her seat on the board and will serve as a strategic adviser but is no longer president and CEO of the firm she founded.
Roche's antibody RG7716 in diabetic macular edema could be a threat to current blockbuster VEGF drugs used for the disease.
AstraZeneca and Amgen’s tezepelumab missed the primary endpoint in a phase 2a atopic dermatitis trial, raising doubts about its prospects.
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.
Teva will pay $250 million to help finish off mid-to-late stage work and then team up on selling Regeneron's experimental NGF antibody fasinumab.
The Medicines Company will have to continue on with a study for its investigational heart drug after an independent body said early data were not strong enough to stop the test early.
Pfizer has posted positive data from two more trials for its new experimental anticholesterol drug bococizumab as the three-way dual for the PCSK9 inhibitor market heats up.